Truist Securities Rates Hinge Health (HNGE) buy, $85 Price Target
Truist Securities has reaffirmed its buy rating on Hinge Health, lifting the price target to $85, a 24.36% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Truist Securities rated Hinge Health, Inc. ($HNGE) "buy" with a $85 price target on June 11, 2026.
Since the rating, $HNGE is up 7.2% after 1 week, up 39.0% after 1 month and up 53.1% to date (from the $64.75 close on Jun 11, 2026).
HNGE
Hinge Health, Inc.
Key Points
- On June 11, 2026, Truist Securities reiterated its buy rating for Hinge Health, Inc. (NYSE: HNGE), increasing the target price to $85.
- Hinge Health shares are currently trading at $68.35, down from a previous close of $105, providing a potential upside.
- The company focuses on automating musculoskeletal care through technology, supporting self-insured employers with a unique health platform.
Get $HNGE trade alerts by text
We text you when insiders, Congress or big funds trade $HNGE. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Hinge Health, Inc. alert may contain errors. Disclosures
Truist Securities Maintains Buy Rating
On June 11, 2026, Truist Securities reiterated its buy rating on Hinge Health, Inc. (NYSE: HNGE) and raised the price target to $85. The stock is currently trading at $68.35, down from a previous close of $105. This reflects a potential upside for investors based on Truist's latest assessment.
Analysts Set New Price Targets
Truist's action comes as the healthcare technology company continues to show growth potential in its market. The company reported a notable revenue increase of 53% in its latest fiscal year, driven by its innovative solutions in musculoskeletal care. The price target increase suggests analyst confidence in Hinge Health's strategic direction and ability to expand its services.
Other Analysts Support Positive Outlook
Hinge Health is receiving favorable ratings from other analysts as well. Keybanc recently maintained an overweight rating with a price target of $140, while Barclays set its target at $110, a notable increase from $100. Needham and Stifel also maintain buy ratings with targets of $115 and $115, respectively. This general analyst consensus reflects positive sentiment around Hinge Health's business model and future growth.
Shares Trading Near Support Levels
Currently, Hinge Health shares are trading at $68.35, which represents a significant drop from its 52-week high of $107. Despite the recent decline, analysts believe the stock has room for growth, especially given its historical performance and current market strategies. The stock's performance is near important support levels, which may attract investors looking for potential rebounds.
$HNGE price target
Hinge Health, Inc. daily closes and this analyst's $85 target. Not advice.
Recent Insider Activity
On June 25, 2026, Insight Holdings Group, LLC purchased 530,982 shares of Hinge Health. Insider buying can indicate confidence in the company's future prospects and might provide additional support for the stock's valuation.
What Hinge Health, Inc. Does
Hinge Health, Inc. focuses on using technology to enhance healthcare delivery, specifically in the musculoskeletal sector. It provides innovative care solutions, including AI-powered tools and wearable devices, primarily for self-insured employers. This strategic focus positions Hinge Health well within the growing healthcare technology market.
What’s Next?
Investors will be closely watching Hinge Health as it approaches its next earnings report scheduled for November 2, 2026. With the recent analyst ratings and insider purchases, market interest in Hinge Health may continue to grow. Remember, the current ratings and targets reflect the company's performance as of this reporting period and may change in the future.
Related Filing Alerts
Source: Truist Securities's rating change on $HNGE (Jun 11, 2026). Written by software, not financial advice. How we make alerts